Metraipolis › archive › dc_030b8565f553

Baseline glucose-to-lymphocyte ratio predicts nivolumab outcomes in advanced non-small cell lung cancer: a multicenter retrospective study — Europe PMC PMID:41766853

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41766853
DOI
10.3389/fimmu.2026.1714533
License (as archived)
solo-consultazione
Archived
2026-11-05T21:48:49.179Z
SHA-256 of the archived text
84a2faac0ea2e6b19bc16f114bf68bb59d5b55287ba521b0def15dd419cefc5f
Stable URL of this page
https://metraipolis.com/documento/dc_030b8565f553

How to cite

Baseline glucose-to-lymphocyte ratio predicts nivolumab outcomes in advanced non-small cell lung cancer: a multicenter retrospective study — Europe PMC PMID:41766853 — Europe PMC (en), https://europepmc.org/article/MED/41766853 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_030b8565f553 (Metraipolis archive dc_030b8565f553, sha256 84a2faac0ea2e6b19bc16f114bf68bb59d5b55287ba521b0def15dd419cefc5f)
BibTeX
@misc{dc030b8565f553,
  title = {Baseline glucose-to-lymphocyte ratio predicts nivolumab outcomes in advanced non-small cell lung cancer: a multicenter retrospective study — Europe PMC PMID:41766853},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41766853},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_030b8565f553; sha256 84a2faac0ea2e6b19bc16f114bf68bb59d5b55287ba521b0def15dd419cefc5f},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41766853. Agents can read the archived copy with the MCP tool read_document.